Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

BioArctic

309.00 SEK+1.51 %19/11 16:07
Less than 1K followers

BIOA B

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
+1.51 %
+7.52 %
-4.22 %
-1.02 %
-0.58 %
+10.28 %
+36.36 %
+150.81 %
+965.52 %

BioArctic is a biopharmaceutical company focused on developing new treatments that address the causes of neurodegenerative diseases. Examples of diseases include Alzheimer's and Parkinson's. A large part of the research is carried out in collaboration with researchers at universities and hospitals. BioArctic was founded in 2003 and is headquartered in Stockholm.

Read more
Market cap
27.42B SEK
Turnover
15.78M SEK
Revenue
2B
EBIT %
62.97 %
P/E
26.75
Dividend yield-%
0.65 %
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
ShowingAll content types

Forum discussions
If you are investing in a company whose goal is to find cures for diseases such as Alzheimer’s, Parkinson’s, and ALS, BioArctic is the right investment for you, as this company’s ambitions are certainly not lacking. In addition, there is evidence, as a drug called Lecanemab has actually...
8/28/2025, 10:21 AM
by Hawkmountdiver
7
About that valuation. What has been the share price development in recent years? A quick read suggests it looks good. If compared to Faron and Herantis companies, this is a safer investment target at this moment.
8/28/2025, 2:16 PM
by j.sälli
2
Brand new Q2 / 2025 below. bioarctic.com wkr0006-146.pdf 1682.08 KB
8/28/2025, 10:28 AM
by Hawkmountdiver
0
Read more on our forum
Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
25/11
2026

Interim report Q3'26

17/2
2027

Annual report '26

Press release2026-11-18 17:17

BioArctic: Nya treårsdata med Leqembi® i klinisk vardag presenterades vid CTAD 2026

BioArctic
Press release2026-11-18 17:17

BioArctic: New three-year real-world data on Leqembi® presented at CTAD 2026

BioArctic
Press release2026-11-18 08:30

Invitation to presentation of BioArctic's third quarter report for July - September 2026 on November 25 at 9:30 a.m. CET

BioArctic

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
Followings and notifications on followed companies
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release2026-11-18 08:30

Inbjudan till presentation av BioArctics rapport för tredje kvartalet juli - september 2026, den 25 november, klockan 9:30

BioArctic
Press release2026-11-17 00:05

BioArctic: Five-year data of continuous Leqembi® treatment show increasing benefit over time

BioArctic
Press release2026-11-17 00:05

BioArctic: Femårsresultaten för kontinuerlig behandling med Leqembi® visar ökande nytta över tid

BioArctic
Press release2026-11-13 08:00

BioArctic: Leqembi[®] Pen subcutaneous treatment launched in Japan

BioArctic
Press release2026-11-13 08:00

BioArctic: Subkutan behandling med Leqembi[®] Pen lanseras i Japan

BioArctic
BioArctic AB, Q3'26
Webcast2026-11-25 09:30

BioArctic AB, Q3'26

BioArctic
Regulatory press release2026-11-02 21:30

BioArctics samarbetspartner Novartis avslutar avtal

BioArctic
Regulatory press release2026-11-02 21:30

BioArctic collaborator Novartis terminates agreement

BioArctic
Press release2026-10-30 15:00

BioArctic's Nomination Committee appointed

BioArctic
Press release2026-10-30 15:00

BioArctics valberedning utsedd

BioArctic
Press release2026-10-30 08:00

BioArctic: New clinical data on lecanemab to be presented at CTAD conference 2026

BioArctic
Press release2026-10-30 08:00

BioArctic: Nya behandlingsdata för lecanemab presenteras vid CTAD-kongressen 2026

BioArctic
Press release2026-10-29 12:21

Redeye: BioArctic: Leqembi Q3 royalties in line with estimates

BioArctic
Regulatory press release2026-10-28 11:00

BioArctic: Sales of Leqembi® totaled 32.2 billion yen in the third quarter 2026

BioArctic
Regulatory press release2026-10-28 11:00

BioArctic: Försäljningen av Leqembi® uppgick till 32,2 miljarder yen under det tredje kvartalet 2026

BioArctic
Press release2026-09-23 16:10

Redeye: BioArctic (Q2 and pipeline review): Iqlik in focus

BioArctic
Press release2026-09-22 16:10

BioArctic: Första patienten behandlad med Leqembi® (lecanemab) i Sverige

BioArctic